bioMérieux HPV test
This article was originally published in The Gray Sheet
Executive Summary
Paris firm launches human papillomavirus (HPV) diagnostic in Europe April 23. The test, which uses NorChip's m-RNA-based Pre-Tect HPV-proofer on bioMérieux's NucliSENS EasyQ platform, is the result of a recently signed license agreement intended to expand the latter firm's footprint in the infectious disease diagnostic market (1"The Gray Sheet" Jan. 22, 2007, p. 21). bioMérieux's molecular diagnostic enables assessment of the virus' oncogenicity, a feature unattainable with viral DNA tests, the firm says. Digene's DNAwithPap is the only FDA-approved test for HPV, the primary cause of cervical cancer. Roche (Amplicor), Gen-Probe (Aptima), Ventana (Inform) and Third Wave Technologies are developing HPV tests...
You may also be interested in...
BioMérieux Moves Forward With HPV, Sepsis Diagnostic Agreements
BioMérieux announced two deals last week as part of its five-year strategic plan focusing on infectious diseases and personalized diagnostics
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.